Synthesis of Benzo[3,4-*h*][1,6]naphthyridines *via* Friedländer Condensation with Active Methylenes

Ramhari V. Rote, Sandeep M. Bagul, Deepak P. Shelar, Sandeep R. Patil, Raghunath B. Toche, and Madhukar N. Jachak*

Organic Chemistry Research Center, Department of Chemistry, K.R.T. Arts, B.H.Commerce and A. M. Science College, Nashik, Maharashtra 422 002, India *E-mail: mnjachak@hotmail.com Received September 25, 2009 DOI 10.1002/jhet.391 Published online 3 December 2010 in Wiley Online Library (wileyonlinelibrary.com).



Novel 4-amino-6-chloroquinoline-3-carbaldehyde has been synthesized by synchronous reduction by lithium aluminiumhydride and finally oxidation with MnO_2 . Friedländer condensation of it with reactive methylenes furnished novel benzo[3,4-*h*][1,6]naphthyridine derivatives.

J. Heterocyclic Chem., 48, 301 (2011).

INTRODUCTION

The construction of ring structures from orthoaminoaldehyde as a starting material has wide applicability for the annulation of heterocyclic systems. This construction method predominates the direction of ring growth (angular vs. linear) and generally permits the direct and regiospecific introduction of functional groups and/or substituents in the newly formed heterocyclic ring. Among numerous possibilities for ortho joined functionalities those containing carbon and nitrogen are of particular interest, because the numerous combinations of their different oxidation states and easy accessibility of simple derivatives provide them with exceptional versatility in hetero annulation reaction. From literature, it was noted that o-aminobenzaldehyde, the first and best known member of this class of compounds has been utilized for synthesis of various heterocycles [1-17]. Annulation reaction of heterocyclic aminoaldehydes provide a synthetic entry into heterocyclic systems fused to pyridine [18-21], pyrazole [22–25], and quinoline nucleus [26,27]. The functionalized quinolines and their benzo/hetero-fused analogous present in numerous natural products along with the wide spectrum of physiological activities [28]. In our earlier communication, we have reported the synthetic utility of heterocyclic o-aminoaldehyde in which annulation of heterocyclic system on to pyrazole and pyrazolopyridine nuclei was performed [29-31].

These literature reports and our continuous interest in this area prompted us to report the novel synthesis of orthoaminoformylquinoline and study of Friedländer condensation of it with various reactive methylenes. In this communication we have synthesized benzo[3,4-*h*][1,6]naphthyridines, which may have potential biological activities such as antimalarials [32], antagonists of 5-HT₄ receptor [33], reported earlier.

Godard and Queguiner reported synthesis of 4-aminoquinoline-3-carbaldehyde by following sequence of reaction [34]. In their sequence, the anhydride I was treated with NH₃ to furnish carboxamide II. The alkaline hydrolysis of II with KOH yielded aminoacid III, which was esterified with MeOH/ H_2SO_4 to yield orthoaminoester IV. The lithium aluminiumhydride reduction of IV yielded primary alcohol V and finally oxidation with MnO₂ furnished a orthoaminoaldehyde **1a** (Fig. 1).

We have adopted different strategy for synthesis of 4amino-6-chloroquinoline-3-carbaldehyde 1b (heterocyclic orthoaminoaldehyde). Chloro-ester A was synthesized in the beginning by reported method [35], starting with p-chloroaniline. Then SN² displacement of chloro functionality at position 4 was achieved with NaN3 in DMF at room temperature to yield **B** quantitatively. The synchronous reduction of both azido and ester group in **B** by lithium aluminiumhydride in dry THF at $0-5^{\circ}C$ yielded the ortho amino alcohol C in 79% yield. Finally, oxidation of C with manganese (IV) oxide, without protecting amino group [34,36], in dichloromethane at room temperature furnish desire target molecule 4-amino-6-chloroquinoline-3-carbaldehyde 1b in 71% yield. In this step, expected N-oxide was not formed as revealed by spectral and analytical data. The



Figure 1. Godard method for synthesis of 4-aminoquinoline-3-carbaldehyde.

intermediates **B**, **C**, and **1b** were characterized by IR, ¹H, and ¹³C NMR, mass spectroscopy and elemental analysis (Scheme 1).

In our approach, the yields of intermediates **B**, **C**, and **1b** are excellent. This method is versatile and scalable. Compound **1b** in hand reacted with alkyl and/or aryl ketones **2a–k** in DMF at reflux using potassium hydroxide (KOH) as a base to yield benzo[*h*] naphthyridines **3a–k** in 68–80% yield. Analogously **1b** when reacted with unsymmetric dialkyl ketones **4a–b**, instead of expected mixture of two isomer [29], only single isomer **5a–b** were obtained in good yield. However, reaction of **1b** with malononitrile **6** under similar reaction condition was unsuccessful. This condensation was achieved by refluxing a mixture of **1b**, malononitrile and piperidine in ethanol to yield benzo naphthyridine **7**, having nitrile and amino functionality ortho to each other, in 78% yield (Scheme 2).

Compounds **3**, **5**, and **7** were characterized by IR, ¹H, and ¹³C NMR, mass spectroscopy and elemental analysis.

The Friedländer condensation can be catalyzed by various reagents [37]. When we extend our synthetic investigation to CH-acidic compounds such as benzoylacetonitrile **8a–d**, β -ketoester **10a**, β -ketoamide **10b**, and diethyl malonate 12, we found that already piperidine as base was sufficient strong to catalyze the condensation reaction. Thus, cyclocondensation of 1b with 8a-d, 10a-b, and 12, afforded 9-Chloro-2-arylbenzo[h][1,6]naphthyridine-3-carbonitriles 9a-d, Ethyl 9-Chloro-2-methylbenzo[*h*][1,6]naphthyridine-3-carboxylate **11a**, 9-Chloro-2-methyl-N-phenylbenzo[h][1,6]naphthyridine-3-carboxamide 11b and Ethyl 9-Chloro-1,2-dihydro-2oxobenzo[h][1,6]naphthyridine-3-carboxylate 13, respectively, in 75-85% yield (Scheme 3). Compounds 9, 11, and 13 were characterized by IR, 1 H, and 13 C NMR, mass spectroscopy and elemental analysis.

In conclusion herein, we report novel and scalable route towards orthoaminoformylquinoline **1b**. A series of novel benzo[3,4-h][1,6]naphthyridines and benzo[3,4-h][3,





h][1,6]naphthyridone was synthesized by Friedländer condensation reaction of 4-amino-6-chloroquinoline-3-carbaldehyde **1b** with reactive methylene compounds.

EXPERIMENTAL

Melting points were determined on a Gallenkamp melting point apparatus, Mod. MFB595 in open capillary tubes and are uncorrected. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were measured on a Varian XL-300 spectrometer using tetra-methylsilane as the internal standard. IR spectra were recorded using a Shimadzu IR-408, a Shimadzu FTIR instrument with potassium bromide discs. Mass spectrum was recorded on Shimadzu GC-MS QP mass spectrometer with an ionization potential of 70 eV. Elemental analyses were obtained on a Hosli CH-Analyzer and are within ± 0.3 of the theoretical percentage.

All reactions were monitored by thin layer chromatography on 0.2 mm silica gel F-254 (Merck) plates using UV light (254 and 366 nm) for detection. Common reagents were either commercially available and were used without further purification or prepared by standard literature procedures.

Ethyl 4-Azido-6-chloroquinoline-3-carboxylate (B). A mixture of A [35] (0.246 g, 1 mmol) and sodium azide (0.065 g, 1 mmol) in DMF (2 mL) was stirred at RT for 2 h. After completion of the reaction (TLC check), the solvent was distilled out by vacuum distillation. The reaction mass was quenched in ice cold water (10 mL) and extracted with three fraction of ethyl acetate (12 mL \times 3). The organic layer was dried over sodium sulphate and solvent was evaporated under reduced pressure. The crude solid was washed with methanol, filtered, and dried to furnish B as colorless solid; (0.182 g, 74%), mp 292-293°C; ir (potassium bromide): 3086(w), 2920(m), 2134(m), 1770(s), 1563(s) cm⁻¹; ¹H NMR (CDCl₃): δ 1.33 (t, J = 6.9 Hz, 3H), 4.45 (q, J = 6.9 Hz, 2H), 7.73 (dd, J = 8.5, 2.2 Hz, 1H), 7.81 (d, J = 2.2 Hz, 1H), 8.23 (d, J =8.5 Hz, 1H), 8.92 (s, 1H); ¹³C NMR (CDCl₃): δ 14.02, 60.3, 124.5, 128.6, 129.4, 131.7, 133.1, 133.9, 138.4, 146.2, 146.9, 166.2; ms: m/z (%) 276 (M⁺,100), 278 (M+2, 32); Anal. Calcd. for C₁₂H₉ClN₄O₂ (276.68): C, 52.09; H, 3.28; N, 20.25. Found: C, 52.25; H, 3.37; N, 20.43.



(4-Amino-6-chloroquinolin-3-yl)methanol (C). A solution of B (0.276 g, 1 mmol) in tetrahydrofuran (2 mL) was added slowly into the dispersed lithium aluminium hydride (0.144 g, 4 mmol) in tetrahydrofuran (2 mL) at 0-5°C, after addition, the reaction mass was allowed to stand at RT and further stirred for 3 h. After completion of reaction (TLC check), the reaction mass was quenched in saturated sodium sulphate solution (2-3 mL) at 0-5°C and extracted in three fraction of ethyl acetate (5 mL \times 3). The combined organic layer was washed with water (5 mL \times 3), then dried over anhydrous sodium sulphate, filtered, and the solvent was evaporated under reduced pressure, the crude solid was washed with methanol, filtered, dried under high vacuum, and recrystallized from ethanol: DMF (8:2) to give C as colorless solid; (0.218 g, 79%); mp 221–222°C; ir (potassium bromide): 3443(m), 3354(m), 3248(s), 2895(w), 1660(s), 1564(s), 1500(s) cm⁻¹; ¹H NMR (DMSO- d_6): δ 4.56 (d, J = 5.4 Hz, 2H, CH₂), 5.13 (t, J = 5.4Hz, 1H, OH), 6.62 (s, 2H, NH₂), 7.55 (d, J = 9 Hz, 1H), 7.76 (d, J = 9 Hz, 1H), 8.36 (s, 1H), 8.37 (s, 1H); ¹³C NMR (DMSO-d₆): δ 56.3, 116.7, 119.4, 122.9, 129.7, 130.5, 131.1, 146.4, 149.2, 151.9; ms: m/z (%) 208 (M⁺,100), 210 (M+2, 33); Anal. Calcd. For C₁₀H₉ClN₂O (208.64): C, 57.57; H 4.35; N, 13.43. Found: C, 57.63; H, 4.46; N, 13.51.

4-Amino-6-chloroquinoline-3-carbaldehyde (1b). To the solution of C (0.208 g, 1 mmol) in dichloromethane (2 mL), manganese (IV) dioxide (0.170 g, 2 mmol) was added. The reaction mixture was stirred at 25°C for 24 h. After completion of the reaction (TLC check), the reaction mass was filtered through celite and solvent was evaporated under reduced pressure, the crude solid was washed with methanol, filtered, dried under high vacuum, and recrystallized from ethanol: DMF (6:4) to give **1b** as pale brown needles; (0.147 g, 71%); mp 319–320°C; ir (potassium bromide): 3323(m), 3093(m), 2926(m), 2783(w), 1714(s), 1657(s), 1589(m) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 7.77 (d, *J* = 8.7 Hz, 1H), 7.80 (d, *J* = 8.7 Hz, 1H), 8.67 (s, 1H), 8.73 (s, 1H), 8.91 (s, 2H, NH₂), 9.96 (s, 1H,

CHO); ¹³C NMR (DMSO- d_6): δ 115.2, 121.5, 123.7, 130.7, 131.8, 133.0, 142.6, 145.3, 159.9, 193.0; ms: m/z (%) 206 (M⁺, 100), 208 (M+2, 31); Anal. Calcd. For C₁₀H₇ClN₂O (206.63): C, 58.13; H, 3.41; N, 13.56. Found. C, 58.23; H, 3.47; N, 13.62.

General procedure for the synthesis of compounds 3ak. A mixture of 1b (0.206 g, 1 mmol) and 2a-k (1 mmol) in DMF with catalytic amount of KOH was heated under reflux for 3 h, after completion of the reaction (TLC check), solvent was evaporated under reduced pressure. The crude solid was washed with methanol, filtered, dried under high vacuum, and recrystallized from ethanol: DMF (7:3) to furnish compounds 3a-k in 68-80% yield.

9-Chloro-2-methylbenzo[h][1,6]naphthyridine (3a). Pale yellow solid; (0.148 g, 72%); mp 282–283°C; ir (potassium bromide): 3111(w), 3040(w), 2833(m), 2830(m), 2905(m), 1671(s), 1659(w), 1561(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 2.47 (s, 3H), 7.73 (d, J = 8.4 Hz, 1H), 7.91 (d, J = 8.4 Hz, 1H), 8.54 (d, J = 8.4 Hz, 1H), 8.75 (d, J = 8.4 Hz, 1H), 9.24 (s, 1H), 9.33 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 24.2, 119.9, 121.4, 122.7, 125.3, 125.9, 130.1, 130.8, 131.1, 133.8, 135.3, 145.6, 156.2; ms: m/z (%) 228 (M⁺, 100), 230 (M+2, 34); Anal. Calcd. For C₁₃H₉ClN₂ (228.66): C, 68.28; H, 3.97; N, 12.25. Found. C, 68.34; H, 4.1; N, 12.31.

9-Chloro-2-phenylbenzo[h][1,6]naphthyridine (3b). Colorless solid; (0.154 g, 75%); mp 298–299°C; ir (potassium bromide): 3022(w), 2979(m), 1668(m), 1639(w), 1567(m), 1559(m), 1518(w) cm⁻¹; ¹H NMR (DMSO-d₆): δ 7.66 (m, 3H, Ar—H), 7.81 (d, J = 8.1 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 8.46 (m, 3H), 8.71 (d, J = 8.4 Hz, 1H), 9.12 (s, 1H), 9.40 (s, 1H); ¹³C NMR (DMSO-d₆): δ 121.2, 123.9, 126.7 (2 C's), 128.0, 128.1, 128.3, 128.9 (2 C's), 130.0, 131.6, 132.7, 133.4, 136.1, 136.9, 144.7, 148.2, 154.3; ms: m/z (%) 290 (M⁺, 100), 292 (M+2, 35); Anal. Calcd. For C₁₈H₁₁ClN₂ (290.75): C, 74.36; H, 3.81; N, 9.63. Found. C, 74.48; H, 3.79; N, 9.77.

9-Chloro-3-methyl-2-phenylbenzo[h][1,6]naphthyridine (3c). Pale yellow solid; (0.164 g, 80%); mp 294–295°C; ir (potassium bromide): 3093(w), 2973(w), 1643(s), 1631(m), 1612(m), 1582(m), 1567(m) cm⁻¹; ¹H NMR (DMSO-d₆): δ 2.31 (s, 3H), 7.22–7.56 (m, 5H), 7.84 (d, J = 7.4 Hz, 1H), 8.01 (d, J = 7.4 Hz, 1H), 8.37 (s, 1H), 8.82 (s, 1H), 9.15 (s, 1H); ¹³C NMR (DMSO-d₆): δ 14.5, 121.7, 124.0, 126.9, 128.6, 129.1, 129.7, 130.1, 130.3, 132.0, 132.4, 132.9, 133.1, 135.2, 135.3, 137.3, 146.6, 150.1, 160.8; ms: m/z (%) 304 (M⁺, 100), 306 (M+2, 32); Anal. Calcd. For C₁₉H₁₃ClN₂ (304.77): C, 74.88; H, 4.30; N, 9.19. Found. C, 74.91; H, 4.43; N, 9.24.

9-Chloro-2-(2-chlorophenyl)benzo[h][1,6]naphthyridine (*3d*). Colorless solid; (0.140 g, 68%); mp 276–277°C; ir (potassium bromide): 2985(m), 2822(w), 2818(m), 1691(m), 1637(w), 1583(w), 1501(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 7.44 (m, 2H), 7.51 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 8.2 Hz, 1H), 7.93 (d, J = 7.5 Hz, 1H,), 8.12 (d, J = 7.5 Hz, 1H), 8.24 (d, J = 6.7 Hz, 1H), 8.42 (d, J = 6.7 Hz, 1H), 9.27 (s, 1H), 9.33 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 120.5, 123.3, 124.9, 126.8, 127.5, 127.9, 128.2, 129.1, 130.3, 131.1, 131.9, 132.4, 132.7, 134.0, 134.7, 145.1, 149.1, 152.7; ms: *m/z* (%) 324 (M⁺, 100), 326 (M+2, 31), 328 (M+4, 18); Anal. Calcd. For C₁₈H₁₀Cl₂N₂ (325.19): C, 66.48; H, 3.10; N, 8.16. Found. C, 66.52; H, 3.19; N, 8.27.

9-Chloro-2-(4-chlorophenyl)benzo[h][1,6]naphthyridine (*3e*). Pale yellow solid; (0.142 g, 69%); mp 269–270°C; ir (potassium bromide): 3012(m), 2921(m), 2817(w), 1658(m), 1649(s), 1486(m), 1422(w), 1583(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 7.37 (d, *J* = 7.9 Hz, 2H), 7.91 (d, *J* = 8.3 Hz, 1H), 8.14 (d, *J* = 8.3 Hz, 1H), 8.36 (d, *J* = 7.2 Hz, 1H,), 8.52 (d, *J* = 7.9 Hz, 2H), 8.65 (d, *J* = 7.2 Hz, 1H), 9.00 (s, 1H), 9.24 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 118.3, 123.0, 127.2, 127.9, 128.9 (2 C's) 130.0, 130.7, 130.9, 131.2, 133.3, 134.1, 134.7, 143.8 (2 C's) 147.2, 154.0, 157.1; ms: *m/z* (%) 324 (M⁺,100), 326 (M+2, 36), 328 (M+4, 13); Anal. Calcd. For C₁₈H₁₀Cl₂N₂ (325.19): C, 66.48; H, 3.10; N, 8.16. Found. C, 66.49; H, 3.21; N, 8.29.

9-Chloro-2-(4-fluorophenyl)benzo[h][1,6]naphthyridine (*3f*). Colorless solid; (0.150 g, 73%); mp 297–298°C; ir (potassium bromide): 2989(m), 2817(w), 1631(m), 1604(m), 1588(m), 1563(m) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 7.55 (d, *J* = 8.4 Hz, 2H), 7.71 (d, *J* = 7.4 Hz, 1H), 7.93 (d, *J* = 7.4 Hz, 1H), 8.06 (d, *J* = 7.5 Hz, 1H), 8.19 (d, *J* = 7.5 Hz, 1H), 8.58 (d, *J* = 8.4 Hz, 2H), 8.90 (s, 1H), 9.26 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 113.4 (2 C's), 120.7, 122.9, 125.6, 125.8, 129.1(2 C's), 129.9, 131.1, 131.9, 132.0, 133.7, 135.1, 144.6, 147.9, 154.1, 159.3; ms: *m/z* (%) 308 (M⁺, 100), 310 (M+2, 33); Anal. Calcd. For C₁₈H₁₀ClFN₂ (308.74): C, 70.03; H, 3.26; N, 9.07. Found. C, 70.11; H, 3.37; N, 9.19.

2-(4-Bromophenyl)-9-chlorobenzo[h][1,6]naphthyridine (**3g**). Pale yellow solid; (0.150 g, 73%); mp 267–268°C; ir (potassium bromide): 3005(w), 2918(m), 1645(m), 1623(w), 1522(m) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 7.25 (d, J = 7.5 Hz, 2H), 7.81 (d, J = 8.5 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 8.37 (d, J = 7.6 Hz, 1H,), 8.56 (d, J = 7.5 Hz, 2H), 8.53 (d, J = 7.6 Hz, 1H), 9.08 (s, 1H), 9.31 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 117.7, 123.5, 126.9, 128.0, 129.0 (2 C's) 131.0, 131.2, 131.3, 131.4, 134.0, 134.2, 134.6, 144 (2 C's) 147.0, 154.4, 159.8; ms: *m*/*z* (%) 368 (M⁺, 78), 370 (M+2, 95), 372 (M+4, 19); Anal. Calcd. For C₁₈H₁₀BrClN₂ (369.64): C, 58.49; H, 2.73; N, 7.58. Found. C, 58.58; H, 2.75; N, 7.69. **9-Chloro-2-(3,4-dimethoxyphenyl)benzo[h][1,6]naphthyridine (3h).** Pale yellow solid; (0.154 g, 75%); mp 294–295°C; ir (potassium bromide): 3018(m), 2963(w), 1683(w), 1669(m) cm⁻¹; ¹H NMR (DMSO- d_6): δ 3.67 (s, 6H), 7.06 (d, J = 7.5Hz, 1H), 7.30 (dd, J = 7.2,2.2 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 8.35 (d, J = 7.4 Hz, 1H), 8.50 (d, J = 8.4 Hz, 1H), 8.75 (d, J = 7.4 Hz, 1H), 9.11 (s, 1H), 9.23 (s, 1H); ms: m/z (%) 350 (M⁺, 100), 352 (M+2, 34); Anal. Calcd. For C₂₀H₁₅ClN₂O₂ (350.80): C, 68.48; H, 4.31; N, 7.99. Found. C, 68.53; H, 4.42; N, 8.1.

9-Chloro-2-(2,6-dimethoxyphenyl)benzo[h][1,6]naphthyridine (3i). Colorless solid; (0.158 g, 77%); mp 297–298°C; ir (potassium bromide): 2981(m), 2897(w), 1676(m), 1632(m), 1548(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.79 (s, 6H), 7.43 (m, 3H, Ar—H), 8.3 1(d, J = 8.2 Hz, 1H), 8.42 (d, J = 7.8 Hz, 1H), 8.45 (d, J = 8.2 Hz, 1H), 8.73 (d, J = 7.8 Hz, 1H), 9.10 (s, 1H), 9.17 (s, 1H); ms: *m/z* (%) 350 (M⁺, 100), 352 (M+2, 36); Anal. Calcd. For C₂₀H₁₅ClN₂O₂ (350.80): C, 68.48; H, 4.31; N, 7.99. Found. C, 68.50; H, 4.37; N, 8.2.

9-Chloro-2-p-tolylbenzo[h][1,6]naphthyridine (3j). Colorless solid; (0.156 g, 76%); mp 297–298°C; ir (potassium bromide): 2981(m), 2978(w), 2896(m), 1635(m), 1618(m), 1512(w) cm⁻¹; ¹H NMR (DMSO- d_6): δ 2.43 (s, 3H, CH₃), 7.37 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 8.10 (d, J = 8.5 Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H), 8.27 (d, J = 8.5 Hz, 1H), 8.44 (d, J = 8.2 Hz, 1H), 8.91 (s, 1H), 9.13 (s, 1H); ms: m/z (%) 304 (M⁺, 100), 306 (M+2, 31); Anal. Calcd. For C₁₉H₁₃ClN₂ (304.77): C, 74.88; H, 4.30; N, 9.19. Found. C, 74.91; H, 4.33; N, 9.27.

2-(3,5-Bis(trifluoromethyl)phenyl)-9-chlorobenzo[h][1,6]*naphthyridine (3k).* Colorless solid; (0.154 g, 75%); mp 283– 284°C; ir (potassium bromide): 3012(m), 2937(m), 1683(w), 1662(s), 1544(m), 1537(w); ¹H NMR (DMSO-*d*₆): δ 7.87 (m, 1H), 8.16 (m, 2H), 8.65 (dd, J = 2.7,8.4 Hz, 1H), 8.80 (dd, J = 2.7,8.4 Hz,1H), 8.93 (s,2H), 9.01 (s, 1H), 9.44 (s, 1H); ms: m/z (%) 426 (M⁺, 100), 428 (M+2, 33); Anal. Calcd. For C₂₀H₉ClF₆N₂ (426.74): C, 56.33; H, 2.11; N, 6.57. Found. C, 56.31; H, 2.17; N, 6.56.

General procedure for the synthesis of compounds 5a and b. A mixture of 1b (0.206 g, 1 mmol) and corresponding ketones 4a-b (1 mmol) in DMF with catalytic amount of KOH was heated under reflux for 3 h. After completion of the reaction (TLC check), solvent was evaporated under reduced pressure, the crude solid was washed with methanol, filtered, dried under high vacuum, and recrystallized from ethanol: DMF (6:4) to furnish 5a-b in 76–79% yield.

9-Chloro-2,3-dimethylbenzo[h][1,6]naphthyridine (5a). Pale yellow solid; (0.160 g, 78%); mp 302–303°C; ir (potassium bromide): 3012(w), 2982(m), 2811(m), 1683(m), 1661(w), 1537(m), 1518(s) cm⁻¹; ¹H NMR (DMSO- d_6): δ 2.55 (s, 3H), 2.71 (s, 3H), 7.86 (d, J = 6.6 Hz, 1H), 8.10 (d, J = 6.6 Hz, 1H), 8.32 (s, 1H) 8.96 (s, 1H), 9.30 (s, 1H); ¹³C NMR (DMSO- d_6): δ 16.3, 18.1, 120.7, 126.6, 127.8, 130.1, 131.3, 132.6, 133.1, 133.2, 135.0, 145.7, 150.0, 159.1; ms: m/z (%) 242 (M⁺, 100), 244 (M+2, 37); Anal. Calcd. For C₁₄H₁₁ClN₂ (242.70): C, 69.28; H, 4.57; N, 11.54. Found. C, 69.37; H, 4.58; N, 11.63.

9-Chloro-2-methyl-3-phenylbenzo[h][1,6]naphthyridine (**5b**). Pale yellow solid; (0.156 g, 76%); mp 291–292°C; ir (potassium bromide): 3314(m), 3017(m), 2983(w), 1683(m), 1676(w), 1560(w), 1553(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 2.60 (s, 3H), 7.22–7.56 (m, 5H), 8.07 (d, J = 7.4 Hz, 1H), 8.29 (d, J = 7.4 Hz, 1H), 8.45 (s, 1H), 9.03 (s, 1H), 9.25 (s, 1H); ms: m/z (%) 304 (M⁺, 100), 306 (M+2, 32); Anal. Calcd. For C₁₉H₁₃ClN₂ (304.77): C, 74.88: H, 4.30; N, 9.19. Found. C, 74.93; H, 4.48; N, 9.21.

2-Amino-9-chlorobenzo[h][1,6]naphthyridine-3-carbonitrile (7). A mixture of 1b (0.206 g, 1 mmol) and malononitrile 6 (0.066 g, 1 mmol) in ethanol with catalytic amount of piperidine was heated under reflux for 2 h. After completion of reaction (TLC check), separated solid was collected by filtration and recrystallized from DMF to furnish compound 7 as colorless needles; (0.160 g, 78%); mp 279-280°C; ir (potassium bromide): 3406(s), 3315(w), 3084(m), 2962(w), 2744(w), 2218(m), 1660(s), 1599(s), 1489(s) cm^{-1} ; ¹H NMR (DMSO d_6): δ 7.86 (d, J = 8.7 Hz, 1H), 7.88 (s, 2H, NH₂), 8.02 (d, J = 8.7 Hz, 1H), 8.75 (s, 1H), 8.89 (s, 1H), 9.05 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 95.2, 119.6, 120.5, 127.3, 127.9, 129.1, 131.2, 133.1, 135.9, 142.7, 146.8, 149.6, 163.0; ms: m/z (%) 254 (M⁺, 100), 256 (M+2, 35); Anal. Calcd. For C₁₃H₇ClN₄ (254.67): C, 61.31: H, 2.77; N, 22.00. Found. C, 61.36; H, 2.86; N, 22.09.

General procedure for the synthesis of compounds 9ad. A mixture of 1b (0.206 g, 1 mmol) and corresponding benzoylacetonitrile 8a-d (1 mmol) in DMF with catalytic amount of piperidine was heated under reflux for 2 h. After completion of the reaction (TLC check), solvent was evaporated under reduced pressure. The crude solid was washed with methanol, filtered, dried under high vacuum, and recrystallized from ethanol: DMF (8:2) to furnish compounds 9a-d in 75–85% yield.

9-Chloro-2-(4-chlorophenyl) benzo[h][1,6]naphthyridine-3carbonitrile (9a). Pale brown solid; (0.170 g, 83%); mp 297– 298°C; ir (potassium bromide): 3002(w), 2987(m), 2811(m), 2217(m), 1678(s), 1657(m), 1583(w), 1559(w) cm⁻¹; ¹H NMR (DMSO-d₆): δ 7.62 (d, J = 7.6 Hz, 2H), 7.91 (d, J = 8.2 Hz, 1H), 8.05 (d, J = 7.6 Hz, 2H), 8.23 (d, J = 8.2 Hz, 1H), 8.54 (s, 1H), 8.81 (s, 1H), 9.17 (s, 1H); ¹³C NMR (DMSO-d₆): δ 91.9, 117.6, 122.2, 123.8, 126.7, 129.1, 129.3, 129.7, (2 C's), 130.1, 131.8, 132.6, 133.1, 133.3, 135.5, 140.3, 144.2, 149.1, 164.4; ms: m/z (%) 349 (M⁺, 100), 351 (M+2, 36), 353 (M+4, 14); Anal. Calcd. For C₁₉H₉Cl₂N₃ (350.20): C, 65.16; H, 2.59; N, 12.00. Found. C, 65.21; H, 2.66; N, 12.11.

2-(4-Bromophenyl)-9-chlorobenzo[h][1,6]naphthyridine-3*carbonitrile* (9*b*). Pale brown solid; (0.166 g, 81%); mp 297–298°C; ir (potassium bromide): 2963(m), 2917(m), 2221(m), 1682(w), 1667(m), 1591(m), 1551(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 7.75 (d, *J* = 7.5 Hz, 2H), 8.01 (d, *J* = 8.4 Hz, 1H), 8.15 (d, *J* = 7.5 Hz, 2H), 8.33 (d, *J* = 8.4 Hz, 1H), 8.15 (d, *J* = 7.5 Hz, 2H), 8.33 (d, *J* = 8.4 Hz, 1H), 8.64 (s, 1H), 8.81 (s, 1H), 9.01 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 90.0, 118.0, 123.2, 126.4, 126.8, 130.2, 130.3, 130.7, (2 C's), 131.1, 131.7, 132.9, 134.1, 134.3, 135.7, 141.0, 143.2, 150.1, 165.3; ms: *m/z* (%) 394 (M⁺, 81), 396 (M+2, 97), 398 (M+4, 22); Anal. Calcd. For C₁₉H₉BrClN₃ (394.65): C, 57.82; H, 2.30; N, 10.65. Found. C, 57.83; H, 2.41; N, 10.72.

2-(3,5-Bis(trifluoromethyl)phenyl)-9-chlorobenzo[h][1,6]naphthyridine-3-carbonitrile (9c). Colorless solid; (0.164 g, 80%); mp 291–292°C; ir (potassium bromide): 3012(m), 2969(m), 2219(m), 1673(w), 1656(m), 1569(m), 1533(w) cm⁻¹; ¹H NMR (DMSO- d_6): δ 7.76 (s, 1H), 8.03 (s, 2H), 8.14 (d, J = 7.5 Hz, 1H), 8.18 (d, J = 7.5 Hz, 1H), 8.64 (s, 1H), 8.83 (s, 1H), 9.38 (s, 1H); ¹³C NMR (DMSO- d_6): δ 89.5, 105.3, 124.1, 124.3, 124.9, 125.7, 126.8, 128.2, 128.8 (2 C's), 131.1, 132.2 (2 C's), 132.9 133.0, 134.7, 138.2, 140.1, 144.3, 147.9, 163.8; ms: m/z (%) 451 (M⁺, 100), 453 (M+2, 31); Anal. Calcd. For C₂₁H₈ClF₆N₃ (451.75): C, 55.87; H, 1.77; N, 9.31. Found. C, 55.83; H, 1.90; N, 9.28.

9-Chloro-(2,5-dimethoxyphenyl) benzo[h][1,6]naphthyridine-**3-carbonitrile (9d).** Pale yellow solid; (0.175 g, 85%); mp 293–294°C; ir (potassium bromide): 2986(m), 2947(w), 2218(m), 1683(w), 1669(w), 1527(m) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 3.65 (s, 6H), 7.01–7.35 (m, 3H, Ar—H), 8.01 (d, J = 8.2 Hz, 1H), 8.23 (d, J = 8.2 Hz, 1H), 8.59 (s, 1H), 8.73 (s, 1H), 9.10 (s, 1H); ms: *m*/*z* (%) 375 (M⁺, 100), 377 (M+2, 33); Anal. Calcd. For C₂₁H₁₄ClN₃O₂ (375.81): C, 69.12; H, 3.75; N, 11.18. Found. C, 69.17; H, 3.81; N, 11.27.

General procedure for the synthesis of compounds 11a and b. A mixture of 1b (0.206 g, 1 mmol) and corresponding diketone 10a-b (1 mmol) in DMF with catalytic amount of piperidine was heated under reflux for 3 h. After completion of the reaction (TLC check), solvent was evaporated under reduced pressure. The crude solid was washed with methanol, filtered, dried under high vacuum, and recrystallized from ethanol: DMF (6:4) to furnish compound 11a-b in 77–79% yield.

Ethyl 9-Chloro-2-methylbenzo[*h*][*1,6*]*naphthyridine-3-carboxylate* (*11a*). Colorless solid; (0.158 g, 77%); mp 297– 298°C; ir (potassium bromide): 3161(w), 3073(m), 2981(m), 2935(m), 1767(s), 1661(s), 1624(m), 1510(m) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 1.33 (s, 3H), 3.78 (t, *J* = 6.9 Hz, 3H), 4.35 (q, *J* = 6.9 Hz, 2H, OCH₂), 7.92 (d, *J* = 8.4 Hz, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.54 (s, 1H), 8.86 (s, 1H), 9.14 (s, 1H); ms: *m*/*z* (%) 300 (M⁺, 100), 302 (M+2, 33); Anal. Calcd. For C₁₆H₁₃ClN₂O₂ (300.74): C, 63.90; H, 4.36; N, 9.31. Found. C, 63.97; H, 4.49; N, 9.30.

9-Chloro-2-methyl-N-phenylbenzo[h][1,6]naphthyridine-3carboxamide (11b). Pale yellow solid; (0.150 g, 73%); mp 271–272°C; ir (potassium bromide): 3336(s), 3152(m), 3017(w), 2880(m), 1693(s), 1642(s), 1624(m), 1517(w) cm⁻¹; ¹H NMR (DMSO- d_6): δ 1.36 (s, 3H, CH₃), 7.34 (m, 5H, Ar—H), 8.01 (d, J = 8.2 Hz, 1H), 8.16 (d, J = 8.2 Hz, 1H), 8.34 (s, 1H), 8.80 (s, 1H), 9.14 (s, 1H), 11.80 (s, 1H, NH); ms: m/z (%) 347 (M⁺, 100), 349 (M+2, 35); Anal. Calcd. For C₂₀H₁₄ClN₃O (347.80): C, 69.07; H, 4.06; N, 12.0. Found. C, 69.14; H, 4.01; N, 12.06.

Ethyl 9-Chloro-1,2-dihydro-2-oxobenzo[*h*][1,6]naphthyridine-3-carboxylate (13). Colorless solid; (0.152 g, 74%); mp 247–248°C; ir (potassium bromide) 3398(w), 3167(m), 3072(m), 2980(s), 1741(m), 1699(s), 1662(s), 1604(s), 1500(w) cm⁻¹; ¹H NMR (DMSO-*d*₆): δ 1.33 (t, J = 6.9 Hz, 3H, CH₃), 4.34 (q, J = 6.9 Hz, 2H, OCH₂), 7.83 (d, J = 7.8 Hz, 1H), 8.02 (d, J = 7.8 Hz, 1H), 8.71 (s, 1H), 9.00 (s, 1H), 9.16 (s, 1H), 12.8 (s, 1H); ¹³C NMR (DMSO-*d*₆): δ 14.1, 60.9, 110.4, 116.9, 122.4, 123.4 131.5, 131.6, 131.8, 142.0, 143.1, 146.2, 151.5, 159.2, 163.6; ms: *m*/*z* (%) 302 (M⁺, 100), 304 (M+2, 34); Anal. Calcd. For C₁₅H₁₁ClN₂O₃ (302.71): C, 59.52; H, 3.66; N, 9.25. Found. C, 59.41; H, 3.67; N, 9.19.

REFERENCES AND NOTES

[1] Fehnel, E. A. J Org Chem 1966, 31, 2899.

[2] Kempter, G.; Andratschke, P.; Heilmann, D.; Krausmann, H.; Mietasch, M. Chem Ber 1964, 97, 16.

[3] Kempter, G.; Hirschberg, S. Chem Ber 1965, 98, 419.

March 2011 Synthesis of Benzo[3,4-*h*][1,6]naphthyridines *via* Friedländer Condensation with Active Methylenes

[4] Nolting, E.; Herzbaum, A. Ber 1911, 44, 2585.

[5] Clemo, R.; Felton, D. G. I. J Chem Soc 1952, 1658.

[6] Markgraf, J. H.; Katt, R. J.; Scott, W. L.; Shefrin, R. N. J Org Chem 1969, 34, 4134.

[7] Liao, T. K.; Nyberg, W. H.; Cheng, C. C. J Heterocycl Chem 1971, 8, 373.

[8] Zalkow, L. H.; Nabors, J. B.; French, K.; Bisarya, S. C. J Chem Soc C 1971, 3551.

[9] Borch, R. F.; Grudzinskas, C. V.; Peterson, D. A.; Weber, L. D. J Org Chem 1972, 37, 1141.

[10] Jacquignon, P.; Croisy, A.; Ricci, A.; Balucani, D. Collect Czech Chem Commun 1973, 38, 3862.

[11] Croisy, A.; Jacquignon, P.; Fravolini, A. J Heterocycl Chem 1974, 11, 113.

[12] Cliff, G. R.; Jones, G.; Woollard, J. McK. J Chem Soc Perkin I 1974, 2072.

[13] Sugasawa, T.; Toyoda, T.; Sasakura, K. Chem Pharm Bull 1974, 22, 771.

[14] Tang, C. S. F.; Morrow, C. J.; Rapoport, H. J Am Chem Soc 1975, 97, 159.

[15] Imai, Y.; Johnson, E. F.; Katto, T.; Kurihara, M.; Stille, J. K. J Polym Sci Polym Chem Ed 1975, 13, 2233.

[16] Eltsov, A. V.; Timpe, H. I.; Rtishchev, N. I. Zh. Org Khim 1975, 11, 398.

[17] Settimo, A. Da.; Primofiore, G.; Livo, O.; Ferrarini, P. L.; Spinelli, S. J Heterocycl Chem 1979, 16, 169.

[18] Hawes, E. M.; Wibberley, D. G. J Chem Soc 1966, 315.

[19] Majewicz, T. G.; Caluwe, P. J Org Chem 1975, 3407.

[20] Hawes, E. M.; Wibberley, D. G. J Chem Soc C 1967, 1564.

[21] Hawes, E. M.; Gorecki, D. K. J.; Gedir, R. G. J Med Chem 1977, 20, 838.

[22] Haufel, J.; Breitmaier, E. Angew Chem Int Ed 1977, 13, 604.

[23] Simay, A.; Takacs, K.; Toth, L. Acta Chim Acad Sci Hung 1982, 109, 175.

[24] Ahluwalia, V. K.; Dahiya, A. Indian J Chem 1996, 35B, 1208.

[25] Ahluwalia, V. K.; Dahiya, A.; Garg, V. K. Indian J Chem 1997, 36B, 88.

[26] Godard, A.; Queguiner, G. J Heterocycl Chem 1980, 17, 465.

[27] Godard, A.; Queguiner, G. J Heterocycl Chem 1982, 19, 1279.

[28] Michael, J. Nat Prod Rep 1997, 14, 605.

[29] Jachak, M. N.; Avhale, A. B.; Tantak, C. D.; Toche, R. B. J Heterocycl Chem 2005, 42, 1.

[30] Jachak, M. N.; Avhale, A. B.; Tantak, C. D.; Toche, R. B. J Heterocycl Chem 2006, 43, 1169.

[31] Jachak, M. N.; Avhale, A. B.; Toche, R. B.; Sabnis, R. W. J Heterocycl Chem 2007, 44, 343.

[32] Roseman, K.; Gould, M.; Linfield, M.; Edwards, B. J Med Chem 1970, 13, 230.

[33] Hinschberger, A.; Butt, S.; Lelong, V.; Boulouard, M.; Dumuis, A.; Dauphin, F.; Bureau, R.; Pfeiffer, B.; Renard, P.; Rault, S. J Med Chem 2003, 46, 138.

[34] Godard, A.; Queguiner, G. J Heterocycl Chem 1980, 17, 465.

[35] Hohn, H.; Janssen, W. J Heterocycl Chem 1972, 9, 235.

[36] Wilfred, C. D. Malays J Chem 2006, 8, 52.

[37] (a) Cheng, C. C.; Yan, S. Y. Org React 1982, 28, 37; (b) Mundy, B. P.; Ellerd, M. G. Name Reactions and Reagents in Organic Synthesis; Wiley: New York, 1982; p 86; (c) Karthikeyan, G.; Perumal, P. T. J Heterocycl Chem 2004, 41, 1039; (d) Diaz-Ortiz, A.; Hoz, de la.; Langa, F. Green Chem 2000, 2, 165.